Jean-Paul Achkar

Dr. Jean-Paul Achkar


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2009 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MSMark S Silverberg
Mark S Silverberg
JCJudy H Cho
Judy H Cho
JRJohn D Rioux
John D Rioux
DMDermot P B McGovern
Dermot P B McGovern
JWJing Wu
Jing Wu
RDRichard H Duerr
Richard H Duerr
Richard Duerr and colleagues present a genome-wide association study of ulcerative colitis. They identify new risk loci on chromosomes 1p36 and 12q15. Ulcerative colitis is a chronic inflammatory disease of the colon that presents as diarrhea and gastrointestinal bleeding. We performed a genome-wide association study using DNA samples from 1,052 individuals with ulcerative colitis and preexisting data from 2,571 controls, all of European ancestry. In an analysis that controlled for gender and population structure, ulcerative colitis loci attaining genome-wide significance and subsequent replication in two independent populations were identified on chromosomes 1p36 (rs6426833, combined P = 5.1 × 10−13, combined odds ratio OR = 0.73) and 12q15 (rs1558744, combined P = 2.5 × 10−12, combined OR = 1.35). In addition, combined genome-wide significant evidence for association was found in a region spanning BTNL2 to HLA-DQB1 on chromosome 6p21 (rs2395185, combined P = 1.0 × 10−16, combined OR = 0.66) and at the IL23R locus on chromosome 1p31 (rs11209026, combined P = 1.3 × 10−8, combined OR = 0.56; rs10889677, combined P = 1.3 × 10−8, combined OR = 1.29).

1 January 2005 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
JAJean-Paul Achkar
Jean-Paul Achkar
MAMohammad Al-Haddad
Mohammad Al-Haddad
BLBret Lashner
Bret Lashner
FRFeza H. Remzi
Feza H. Remzi
ABAaron Brzezinski
Aaron Brzezinski
VFVictor Fazio
Victor Fazio

1 June 2004 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
JWJason M. Wolf
Jason M. Wolf
JAJean-Paul Achkar
Jean-Paul Achkar
BLBret A. Lashner
Bret A. Lashner
CDConor P. Delaney
Conor P. Delaney
RPRobert E. Petras
Robert E. Petras
VFVictor W. Fazio
Victor W. Fazio

11 December 2018 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
GSGengqing Song
Gengqing Song
CFClaudio Fiocchi
Claudio Fiocchi
JAJean-Paul Achkar
Jean-Paul Achkar
Scientific research into the effects and mechanisms of acupuncture for gastrointestinal diseases including inflammatory bowel disease has been rapidly growing in the past several decades. In this review, we discuss the history, theory, and methodology of acupuncture and review potentially beneficial mechanisms of action of acupuncture for managing inflammatory bowel disease. Acupuncture has been shown to decrease disease activity and inflammation via increase of vagal activity in inflammatory bowel disease. Acupuncture has demonstrated beneficial roles in the regulation of gut dysbiosis, intestinal barrier function, visceral hypersensitivity, gut motor dysfunction, depression/anxiety, and pain, all of which are factors that can significantly impact quality of life in patients with inflammatory bowel disease. A number of clinical trials have been performed to investigate the therapeutic effects of acupuncture in ulcerative colitis and Crohn’s disease. Although the data from these trials are promising, more studies are needed given the heterogeneous and multifactorial aspects of inflammatory bowel disease. There is also an important need to standardize acupuncture methodology, study designs, and outcome measurements.

29 November 2010 in Gut
Verified
Journal Article
Closed access
PDF file
TATasneem Ahmed
Tasneem Ahmed
FRFlorian Rieder
Florian Rieder
CFClaudio Fiocchi
Claudio Fiocchi
JAJean-Paul Achkar
Jean-Paul Achkar
The majority of patients with Crohn's disease (CD) require surgery during the course of their disease, but such surgery is typically not curative. Although some studies suggest that the disease state is theoretically reset to its earliest phase following surgery, disease phenotype and natural history of CD do not change significantly after surgery, leading to high rates of recurrence. Factors predisposing to this recurrence are not well defined, so there is a need for and a unique opportunity to develop a better understanding of the pathogenesis of recurrent inflammation and associated risk factors after an ileocolic resection. This paper reviews the postoperative disease outcome and evolution based on defining the combination of the patient's microbial flora, environmental exposure history, immune response and genetic make-up.

1 July 2004 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
JAJean-Paul Achkar
Jean-Paul Achkar
TSTyler Stevens
Tyler Stevens
KEKirk A Easley
Kirk A Easley
ABAaron Brzezinski
Aaron Brzezinski
DSDouglas Seidner
Douglas Seidner
BLBret Lashner
Bret Lashner
Objectives. There is some uncertainty regarding how to best dose and therapeutically monitor 6-mercaptopurine or azathioprine in patients with inflammatory bow